Cellular and Mitochondrial Pathways Contribute to SGLT2 Inhibitors-mediated Tissue Protection: Experimental and

Raúl Lelio Sanz1, Sebastián García Menéndez1,2, Felipe Inserra3

  • 1Departamento de Patologie et Pharmacologie, Instituto de Medicina y Biologia Experimental de Cuyo, Consejo Nacional de Investigación Cientifica y Tecnológica (IMBECU- CONICET), Mendoza 5500, Argentina.

PubMed

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular health by enhancing mitochondrial function and reducing oxidative stress and inflammation in metabolic disorders. These drugs offer a promising therapeutic strategy for protecting cardiac tissue and preventing adverse events.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Mitochondrial Biology

Background:

  • Compromised mitochondrial function drives cardiovascular disease in metabolic syndrome and diabetes.
  • Angiotensin II and low sirtuin activity exacerbate oxidative stress, inflammation, and cardiac remodeling.
  • Reduced mitochondrial energy production is a hallmark of metabolic disorders.

Purpose of the Study:

  • To investigate the role of SGLT2 inhibitors (SGLT2i) in modulating mitochondrial function and related pathways in cardiovascular disease.
  • To elucidate the mechanisms by which SGLT2i exert cardioprotective effects in the context of metabolic disorders.

Main Methods:

  • Review of randomized clinical trials and mechanistic studies on SGLT2 inhibitors.
  • Analysis of SGLT2i effects on mitochondrial efficiency, oxidative stress, inflammation, and autophagy/mitophagy.
  • Exploration of the interplay between sirtuins, AMPK, and hypoxia-inducible factors.

Main Results:

  • SGLT2 inhibitors significantly improve cardiac function and reduce cardiovascular and renal events.
  • SGLT2i enhance mitochondrial efficiency, decrease oxidative stress, and reduce inflammation.
  • SGLT2i promote autophagy and mitophagy, clearing cellular debris and protecting cardiac tissue.

Conclusions:

  • SGLT2 inhibitors demonstrate profound beneficial effects on mitochondrial function, offering a potent therapeutic strategy for cardiovascular protection in metabolic disorders.
  • SGLT2i act as 'cellular supermolecules' by improving mitochondrial efficiency and reducing inflammation.
  • Further research into SGLT2i's mitochondrial actions may unlock novel therapeutic avenues for cardiovascular health.

Related Concept Videos

Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
7.0K
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.6K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Transcellular Transport of Solutes01:23

Transcellular Transport of Solutes

Transcellular transport of solutes is the movement of substances like monosaccharides and amino acids through polarized cells. This transport mechanism is primarily seen in epithelial and endothelial cells aided by membrane transport proteins such as channels and transporters. The tight junctions between these cells confine the membrane proteins to the two sides of the cell. The epithelial cells have distinct apical and basolateral domains. In contrast, the endothelial cells show the luminal...
3.6K